TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04543058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeatPark Application
Description: The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BeatPark Application without synchronized music
Description: The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BeatPark Application without music
Description: The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
Study: NCT03337542

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AR101
Description: AR101
Study: NCT00282178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25-50 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16-32 mg once daily 12 weeks
Study: NCT03021395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine at a dose of 20mg/㎡/d on day 1-5.
Study: NCT03352700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3L PEG
Description: Group A patients (n = 300) used only 3L PEG before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3L PEG+Dyclonine Hydrochloride Mucilage
Description: Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
Study: NCT02726971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
Study: NCT00199914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Description: continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shortwave diathermy
Description: continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
Study: NCT02786134

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
Study: NCT05075395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARO therapy seal
Description: PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
Study: NCT02765087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical History
Description: Oriented Survey and complete physical exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical History
Description: Oriented Survey and complete physical exam.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Nose
Description: Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Nose
Description: Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pleural Fluid Analysis
Description: Cytomorphology Cytochemistry Adenosine Deaminase Value

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pleural Fluid Analysis
Description: Cytomorphology Cytochemistry Adenosine Deaminase Value
Study: NCT01611064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air
Description: Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
Study: NCT04139044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training for Stable Ankle
Description: Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training for Unstable Ankle
Description: Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
Study: NCT02410655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
Study: NCT03339869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
Study: NCT03122275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized text message invitation ( Step 1a)
Description: Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized automatic phone call invitation (Step 1b)
Description: Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secretary phone call (Step 2)
Description: Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health professional face-to-face appointment (Step 3)
Description: Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Letter
Description: A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm.
Study: NCT02777697

Intervention type: OTHER
Intervention: chronic pain
Study: NCT04494230

Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.

Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.

Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.

Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.

Intervention type: BEHAVIORAL
Intervention: Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities
Description: to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
Study: NCT01406288

Intervention type: OTHER
Intervention: HUS standard coverage care (including in ICU)
Description: HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
Study: NCT01088464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 800 mg intravenously, every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: 800 mg intravenously, Days 1 and 8 every 3 weeks
Study: NCT01974089

Intervention type: OTHER
Intervention: Dysphagia
Description: Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
Study: NCT01611948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 125mg/day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125mg/d placebo pill for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study: NCT01460095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HbA1c measurement and education
Description: three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
Study: NCT00749879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
Study: NCT03985475

Intervention type: OTHER
Intervention: skin sample
Description: For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
Study: NCT04807699

Intervention type: OTHER
Intervention: Data collection
Description: Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
Study: NCT01128361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
Study: NCT01121523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue directed tactile stimulation
Description: Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue directed tactile stimulation
Description: Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
Study: NCT04085341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-102
Description: Intravitreal injection of GB-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-102
Description: Intravitreal injection of GB-102
Study: NCT01891097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study: NCT02393677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.5% 30 ml was used to block brachial plexus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine with Dexmedetomidine
Description: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
Study: NCT04249323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176 Lipid Capsule Formulation
Description: CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176 Lipid Capsule Formulation
Description: CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT113176 Lipid Capsule Formulation
Description: CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176 Lipid Capsule Formulation
Description: Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT113176 Lipid Capsule Formulation
Description: Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
Study: NCT02338011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
Study: NCT02293850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
Study: NCT01117454

Intervention type: DRUG
Group type: OTHER
Intervention: Flecainide Acetate
Description: oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Intervention type: DRUG
Group type: OTHER
Intervention: Flecainide Acetate
Description: oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, similar in appearance to flecainide

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, similar in appearance to flecainide

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.